IMP

Methionine and the China Dependency

How Feed Additives Got Caught in the Geopolitical Crossfire

China overcapacity. Energy cost pressure. The breaking point. Where AI fits. What governments, companies, and markets must do.

Animal Nutrition | Geopolitical Risk | Feed Additives | China Dependency

KEY FIGURES

+50%
Potential global methionine capacity increase from China alone by early 2030s

87%
US methionine imports sourced from China, 2024

~€300M
Evonik EBITDA from methionine, 2024 (Berenberg est.)

~2030
Year methionine may become a 'structurally low-margin' commodity (Berenberg)

April 2026 | IMP InterMediaPartners | www.intermediapartners.de

All data from publicly available sources

1 Executive Summary

Methionine — a sulphur-containing essential amino acid that animals cannot synthesise themselves — is one of the most strategically important feed additives in modern livestock production. Its absence from the diet directly limits protein synthesis, growth rates, and feed conversion efficiency across poultry, swine, and aquaculture. For roughly three decades, the western producers that mastered its industrial synthesis — Evonik, Adisseo/Bluestar, Novus International — held technology leadership, pricing power, and the margins that came with both. That era is closing.

China is adding methionine production capacity at a scale and pace that western incumbents cannot match on cost. Berenberg estimates China will add approximately 1.5 million tonnes of cumulative methionine capacity by the early 2030s — potentially increasing global capacity by more than 50%. The same research house warns that methionine 'may fall into an economically troubled category of structurally low-margin chemicals by around 2030.' The US already sources 87% of methionine imports from China. For Evonik, methionine generated an estimated €300 million in EBITDA in 2024 — a cash flow that could structurally erode within this decade.

+50%
Potential global capacity increase from China alone by early 2030s (Berenberg est., Jan 2026)

87%
US methionine imports from China in 2024 — structural dependency (IFERA / ResearchAndMarkets)

~€300M
Evonik EBITDA from methionine in 2024 — the cash cow (Berenberg estimate)

6–9%
Global methionine market CAGR 2025–2030 — demand growing but not fast enough

This paper examines the competitive, geopolitical, and structural pressures on the western animal nutrition industry, maps the potential breaking points, assesses what path forward remains open — and asks specifically whether artificial intelligence can close enough of the cost gap to matter.

The Central Question

Is methionine production in the West structurally doomed by Chinese overcapacity, high energy costs, and regulatory burden — or is there a path through? If so, what does it require from companies, governments, and markets? And where exactly is the breaking point?

2 What Methionine Is — and Why It Is Structurally Non-Substitutable

DL-Methionine is the first limiting amino acid in poultry diets — meaning it is the amino acid most likely to be in short supply relative to the animal's requirements, acting as the bottleneck that limits all other protein utilisation. When methionine is deficient, the animal's body cannot use the remaining dietary protein efficiently, regardless of how much of it is present. The result is suppressed growth rates, poorer feed conversion ratios, and in severe cases, immune dysfunction.

Methionine serves additional biological roles beyond protein synthesis: it is the precursor for cysteine, taurine, and glutathione; it donates methyl groups essential for epigenetic regulation and metabolic function; and it carries the sulphur that is critical for feather formation in poultry and coat quality in swine. There is no practical substitute at scale. Plant-based feed ingredients — soy, corn, rapeseed — contain insufficient methionine relative to animal requirements, making supplementation not optional but operationally mandatory in commercial livestock production.

Metric	Figure	Context
Global methionine market value, 2024	~$3,67B	Range reflects varying market scope definitions across sources
Global methionine demand, 2025	~1.94M tonnes	Mordor Intelligence; projected to reach 2.64M tonnes by 2030
Feed-grade applications share	~89,14%	Pharmaceutical, food, and supplement uses form the remainder
Poultry feed — share of methionine use	~46%	Largest single end-use; broiler production growth drives baseline demand
Swine feed — share	~25%	Second-largest; precision nutrition adoption increasing inclusion rates
Aquaculture — share	~18%	Fastest-growing application as fishmeal replacement accelerates
Global chicken meat production, 2025	~104.9M tonnes	USDA FAO projection; record level — direct demand driver
Market CAGR 2025–2030 (consensus range)	6–9%	Demand trajectory confirmed across multiple independent sources. Grand View Research puts this at 9.2%, Mordor Intelligence at 6.41%, and Intel Market Research at 4.3%, depending on methodology and scope definition.
Solid DL-Methionine — product share	~70%	Dominant form; liquid methionine growing at faster rate
Bio-based methionine share (2024)	~15%	Synthetic/petrochemical-derived still ~85% of global production

Sources: Mordor Intelligence 2026; Grand View Research 2025; Precedence Research 2025; Industry Research Biz 2025; USDA FAO October 2024. Market valuation figures vary substantially across sources due to differing scope definitions (feed-grade only vs. all applications), geographic perimeters, and base year methodologies. Figures should be read as directional.

THE METHIONINE CASCADE — WHAT STOPS WHEN SUPPLY STOPS

Methionine feeds every subsequent stage — a supply disruption propagates forward within days

The cascade above illustrates why methionine sits at a position of disproportionate criticality in the food supply chain. A shortage does not slow production incrementally — it stops it. A broiler house running out of methionine on week three of a seven-week grow-out cycle cannot substitute another nutrient. The birds' growth stalls, feed conversion degrades, and the production schedule that ties into slaughter, processing, and retail supply chains fractures. This is not apharmaceutical supply chain where buffer inventory is measured in months. In commercial poultry, it is measured in days.

3 The Competitive Landscape: Who Produces What, and Where

The global methionine market is highly concentrated at the top, with four western producers historically commanding the technology leadership and the pricing premium that accompanied it. That structure is under active and accelerating pressure from Chinese capacity expansion funded by state-backed financing, lower energy costs, and a domestic policy environment that actively incentivises amino acid self-sufficiency.

Producer	Market Share	Key Developments 2024–2026
Evonik Industries (DE)	~30–35% global, ~44% of reported non-Asian capacity	MetAMINO (DL-methionine). Three global hubs: Singapore (340,000t/yr —expanded Aug 2024), Antwerp/ Wesseling (upgraded 2025), US Gulf Coast. Announced 10% price increase March 2026; 5–8% increase May 2025. Estimated €300M methionine EBITDA in 2024 (Berenberg).
Adisseo/Bluestar (FR/CN)	~25% global	Rhodimet (liquid MHA-FA) and Smartamine. Deeply embedded in China: $681.2M committed to 150,000t/yr Fujian facility (start-up 2027). Double-digit revenue and gross profit growth in 2024. Nanjing expansion 2024.
Novus International (US)	~34% of non-Asian capacity	HMTBA (Alimet liquid MHA). Ginkgo Bioworks partnership (Sep 2024) for advanced enzyme development. Acquired BioResource International (Mar 2024).
Sumitomo Chemical (JP)	Significant Asia share	ITOCHU Corporation to exclusively distribute MetAMINO from Ehime facility from April 2025, expanding existing distribution partnership. (Source: Mordor Intelligence, February 2026 — pharmaceutical-grade claim not independently verified from primary source.)
CJ CheilJedang (KR)	Growing share	Operates 80,000 t/yr L-methionine plant in Kerteh, Malaysia (with Arkema; commissioned January 2015) — world's first bio-methionine facility at commercial scale. Fermentation capacity expansion in South Korea announced February 2025. Bio-fermentation route reduces carbon emissions per tonne versus petrochemical synthesis.
Zhejiang NHU (CN)	Significant Chinese domestic	New DL-methionine unit opened H2 2023. Growing Chinese domestic player with export ambitions.
Sichuan Hebang (CN)	Growing domestic	New 70,000t/yr production line completed 2025; +9% domestic market share increase.
Chongqing Unisplendour (CN)	Domestic	State-backed. Contributing to Chinese capacity expansion alongside NHU and Hebang.

Sources: Industry Research Biz; Mordor Intelligence; Barclays/Investing.com March 2026; Berenberg January 2026; Evonik press releases 2025–2026; Adisseo/ChemChina February 2025.

The Structural Shift in One Number

Asia accounts for 64% of global methionine capacity today, with China at 35% and the rest of Asia at 29%. Evonik holds 44% of non-Asian capacity — making it the largest producer outside the region, ahead of Novus at 34% and Adisseo at 19% of non-Asian capacity. China's total feed amino acid capacity already exceeds 4.89 million metric tonnes per year. If Berenberg's estimate of 1.5 million additional tonnes by the early 2030s is accurate, global methionine capacity increases by more than 50% from Chinese expansion alone — at costs western producers cannot match.

Producer	Capacity	Location	Status
Evonik	+40,000 t/yr	Singapore	Completed 2024
Adisseo	150,000 t/yr	Fujian, China	Announced 2024, start 2027
Zhejiang NHU	New DL.Met Unit	China	Opened H2 2023
Sichuan Hebang	70,000 t/yr	China	Completed 2025
CJ CheilJedang	Fermentation expansion	South Korea	Announced Feb 2025

Additional Chinese capacity from Chongqing Unisplendour and other domestic producers is reported in trade sources but without confirmed volumes. The Berenberg 1.5M tonne projection for the early 2030s aggregates these and additional unannounced projects.

4 How the Price Mechanism Works — and Where It Breaks

Methionine pricing has oscillated between boom and bust in a pattern that maps closely to the Chinese capacity cycle. When Chinese capacity is constrained — by maintenance, logistics disruption, or raw material shortages — spot prices spike and western producers expand margins. When Chinese capacity comes online at scale, prices collapse to cash-cost levels that western producers struggle to sustain profitably. Methionine price benchmarks fluctuate with methanol and acrolein feedstock costs, freight rates, and seasonal demand cycles. As of Q1 2025, IMARC Group reported DL-methionine prices of approximately US$3,017 per tonne in the USA and US$2,782 per tonne in China, reflecting the logistics premium western buyers carry on top of Chinese production prices. Long-run price series covering more than 3–5 years are not publicly available from primary sources; the cycle analysis below is drawn from disclosed company commentary and trade press reporting.

DL Methionine Prices Outlook Q3 2025 (Source: IMARC Group)

- USA: USD 2946/MT
- China: USD 2673/MT
- Germany: USD 2778/MT
- Malaysia: USD 2255/MT
- South Africa: USD 2466/MT

4.1 The 2022–2026 Price Cycle

Period	Price Environment	Key Dynamics
2021–2022	Strong pricing	Post-COVID demand recovery; supply chain disruptions constrain output. Evonik records group price gains of +10% (2021) and +18% (2022).
2023	Collapse	Destocking cycle; demand weakness; Chinese capacity resumption. Evonik group prices contract –2%. Methionine prices 'significantly below prior-year quarter' (Evonik Q3 2023). Evonik implements €250M cost savings programme.
2024	Partial recovery	Red Sea disruption increases freight costs and supports prices via logistics premium. DL-methionine prices trend upward through H2 2024 on seasonal demand and stockpiling. Group prices still –2% YoY for Evonik. Berenberg estimates €300M methionine EBITDA.
Jan 2025	Coordinated hikes	Evonik +7%, Adisseo liquid +5%, New Hope Liuhe solid +15%. Lifted landed costs in China by 5–7%. Downstream rationing as millers defer.
May 2025	Another increase	Evonik raises MetAMINO globally by 5–8% effective immediately. Partial shutdown of Antwerp & Wesseling (8–10 weeks) for investment.
Aug 2025	Disruption window	Evonik optimises global production setup Q3/Q4 2025. Barclays estimates ~€450M EBITDA delta if Asian availability tightens, volumes shift to non-Asian producers.
Mar 2026	Further hike	Evonik announces +10% price increase for MetAMINO globally, effective immediately. Suggests continued supply tightness or confidence in demand. Adisseo Fujian 150,000t facility still on track for 2027 start-up.

4.2 The Three Cost Disadvantages Western Producers Cannot Eliminate

Structural Cost Disadvantages	The Chinese Advantage Mechanism
• EU industrial electricity prices averaged approximately €0.199/kWh in 2024 (Eurostat); comparable Chinese industrial rates are estimated at approximately €0.082/kWh (Cefic Q2 2025 benchmark). This represents a differential of roughly 2.4× — a structural gap driven by energy mix and industrial energy policy, not cyclical pricing.	• Capital cost advantage: Chinese state policy has explicitly targeted amino acid self-sufficiency. New facilities in Sichuan and Chongqing benefit from land use rights, grid connection subsidies, and access to state-policy-backed lending at rates unavailable to European chemical companies. Adisseo's $681M Fujian facility represents the western response — building in China to compete in China. Evonik's Singapore hub is the equivalent logic for Asia
• Labour and overhead costs in European chemical operations are among the highest globally; regulatory compliance under REACH, CSRD, and incoming PPWR adds further cost layers. Precise multipliers versus Chinese operations are not available from public comparative studies and are therefore not stated here.	• Raw material proximity: Chinese producers are proximate to sulphur, methanol, and acrolein supply chains that feed methionine synthesis. European producers must import key precursors or operate integrated sites at significant scale to be competitive. The Antwerp Verbund model (integrated chemical park) is the European answer — but it is replicable only where the industrial infrastructure already exists
• Regulatory compliance cost: EU REACH registration, CSRD reporting obligations, Carbon Border Adjustment Mechanism (CBAM) transition from 2026, and incoming packaging regulations all add cost layers that Chinese competitors do not carry in their domestic cost structure	• Export-driven overcapacity: Chinese producers do not need to be profitable on every export tonne — domestic market margin subsidises export volume, keeping prices globally depressed. This is the same dynamic that destroyed western solar panel, wind turbine, and battery manufacturing — and it is structurally identical in feed amino acids

The Lysine Lesson: A Historical Roadmap for Methionine

To understand the future of methionine, one must look at the Lysine Collapse of the early 2000s. Lysine serves as a cautionary tale of how rapid Chinese capacity expansion can dismantle a high-margin Western specialty chemical market in under a decade.

1. From High-Margin Specialty to "Penny Commodity"
In the 1990s, Lysine was a high-value fermented amino acid dominated by a "triopoly": ADM (US), Ajinomoto (Japan), and Kyowa Hakko (Japan). These players maintained high prices through technology leadership and, infamously, a global price-fixing cartel. When the cartel was busted and Chinese producers (led by GBT and later Meihua) entered the market, they didn't just compete—they flooded it. Global prices crashed from over $2.50/kg to below $1.00/kg almost overnight.

2. The Structural Exodus: Western incumbents faced a brutal choice:
Exit: Many European and North American plants were shuttered or converted because they could not match the Chinese "Subsidized Scale" model (cheap corn feedstock + state-backed CAPEX).
Consolidation: The market moved from dozens of players to a few massive "low-cost champions."

3. The "Value-Add" Pivot
The survivors (like Ajinomoto) realized they could no longer win on the "tonnage of white powder." They pivoted to specialty formulations: bypass-lysine for ruminants, high-purity pharmaceutical grades, and "liquid lysine" integrated into digital feed-mill services.

The Warning for Methionine:
Methionine is currently where Lysine was in 2005. The "Lysine Lesson" proves that once Chinese capacity exceeds global demand by 20-30%, brand loyalty and historical technology leadership evaporate. Survival for Western producers like Evonik and Novus depends entirely on their ability to move "upstream" into bio-based sustainability and "downstream" into AI-driven precision nutrition before the $1.5M tonne wave of Chinese capacity fully makes landfall.

5 The Breaking Point: Where and When

The question 'where is the breaking point?' deserves a structured answer. The breaking point is not a single event — it is a threshold below which western methionine production becomes impossible to justify as a stand-alone business, triggering either exit, consolidation, or transformation into a fundamentally different value proposition.

Breaking Point Category	Description	Source / Note
Price floor test	If methionine spot prices fall and remain below ~€1,500–1,800/tonne (approximately western full-cost production cost at current energy levels), western incumbents operate at cash-cost loss on spot volume. Chinese producers, with lower cost bases and state support, can sustain this level indefinitely. Western producers cannot.	Approximate. Varies significantly by site, energy contract, and integration.
Capacity utilisation threshold	Methionine plant economics depend on high utilisation rates (typically 85%+ for profitability). If Chinese overcapacity depresses prices and volume simultaneously, western plants face a double squeeze: lower revenue per tonne and lower volumes. Below ~70–75% utilisation, fixed cost recovery becomes unsustainable.	Industry standard; specific thresholds are commercially sensitive.
EBITDA erosion signal	Berenberg estimated Evonik generated ~€300M EBITDA from methionine in 2024. The analyst projects prices falling by 'low-single-digit percentages' in 2026 and 2027, suggesting the company 'could be in the early stages of unwinding price increases from the early 2020s.' A sustained return to 2023 price levels would compress this materially.	Berenberg January 2026.
The ~2030 structural transition	Berenberg's explicit forecast: methionine 'may fall into an economically troubled category of structurally low-margin chemicals by around 2030.' This is the analyst equivalent of calling an industry-wide breaking point. It does not mean western producers disappear — it means their business model must change to survive.	Berenberg January 2026.
The Adisseo paradox	Adisseo — nominally a French company, majority owned by Chinese state enterprise Bluestar/ChemChina — committed $681.2M to a Chinese facility in January 2024 while simultaneously competing in European markets. This is not breaking; it is adaptation via ownership structure. The strategy acknowledges that Chinese cost structures require Chinese production to be viable long-term.	Mordor Intelligence 2026; ChemChina investor communications.

The breaking point for individual companies arrives at different thresholds depending on their cost structure, integration depth, and strategic alternatives. Evonik, with three globally distributed production hubs and deep amino acid analytics and services capabilities, is better positioned to manage the transition than a single-site producer. Smaller feed additive companies that source methionine as a traded commodity and add value through formulation will feel Chinese price pressure earlier and more acutely.

6 The Downstream Cascade: What This Means for Animal Nutrition

Methionine pricing and availability are not merely a problem for chemical manufacturers. They are a structural determinant of animal protein production economics across every major livestock sector. When methionine prices decline — driven by Chinese overcapacity — farmers benefit from lower feed costs. But when supply becomes geopolitically unreliable, the same farmers face production-stopping shortages with no short-term substitute available.

Sector	Methionine Dependency and Disruption Impact	Time to Visible Impact
Poultry — broilers	Methionine inclusion is non-negotiable. A 7-week grow-out cycle cannot be paused waiting for supply. A supply disruption in week 3–4 compromises the entire batch. US broiler production alone requires millions of tonnes of supplemented feed annually. No methionine = immediate growth suppression within 48–72 hours. The structural dependency is not hypothetical: the Institute for Feed Education and Research reported in 2024 that the United States sourced 87% of its methionine imports from China (IFEEDER / ResearchAndMarkets, 2024). During COVID-19-related shipping disruptions in 2021–2022, several US and European feed compounders reported temporary methionine allocation constraints and formula substitution costs as spot prices rose more than 40% within a single quarter.	Days to impact
Poultry — layers	Egg production and shell quality directly linked to methionine sufficiency. Laying hens under methionine stress reduce production and show deteriorating shell quality within 5–7 days. Europe's 400M+ laying hens are effectively methionine-dependent.	Days to impact
Swine	Methionine drives muscle protein accretion in finishing pigs. Less acute than poultry but still a hard constraint. Chinese pork supply — world's largest — is also dependent on methionine supplementation; domestic supply priority would likely be maintained in a disruption scenario.	1–2 weeks to impact
Aquaculture	Fastest-growing application. Fish meal replacement diets have insufficient methionine — supplementation is mandatory. Global aquaculture feed demand exceeded 100M tonnes in 2024. Shrimp and salmon farming particularly sensitive to amino acid quality.	Variable — species dependent
Feed compounders and premix industry	Companies producing complete feed or premix products have methionine as a cost line item of significant weight. Chinese price competition compresses their input cost but also removes pricing power vis-à-vis customers. Communication investment reduces as companies manage costs — the segment becomes quieter even as the science and regulatory complexity increases.	Immediate and ongoing
Western animal nutrition companies (Evonik, Novus, Adisseo)	Margins under pressure from commoditisation. Response strategies include moving up the value chain (analytics, feed optimisation software, precision nutrition services), geographic diversification, and portfolio extension into adjacent additives (probiotics, enzymes). Communication becomes a differentiator — technical depth matters when the product itself is commoditised.	Structural and multi-year

7 Is There a Path Through? What Companies, Governments, and Regulators Can Do

The path through is not comfortable, and it is not guaranteed. But it is not closed. The western animal nutrition industry has several structural advantages that Chinese producers cannot easily replicate: decades of nutritional science, global customer relationships, regulatory trust, and the ability to build service layers around commodity products that Asian competitors struggle to match. The question is whether companies and their governments act on these advantages before the price window closes permanently.

7.1 What Companies Can Do

Company-Level Strategies	Structural Responses
• Move from selling tonnes to selling outcomes: Evonik's MetAMINO ATLAS (19-site global trial programme proving 65% bioavailability superiority over competitor MHA products) is precisely this — converting a commodity product into a scientifically substantiated performance claim. If you can show that 65 units of MetAMINO replaces 100 units of Chinese competitor product on a per-bird performance basis, you are no longer competing on price per tonne	• Invest in bio-based routes: CJ CheilJedang's 2024 bio-based methionine fermentation project reduces carbon emissions by 15% per tonne of production. METEX NØØVISTAGO's legume-derived methionine (March 2025) serves EU non-GMO and clean-label regulatory requirements. Bio-fermentation routes are currently higher-cost but are attracting regulatory and ESG premium that chemical synthesis cannot access.
• Build the precision nutrition platform: the real moat is not the molecule — it is the optimised diet formulation built around it. Companies that own the nutritional modelling software, the farm-level performance data, and the technical advisory relationship with integrators and compounders are not selling methionine. They are selling feed cost reduction — which is a different market with different pricing dynamics	• Consolidation: Berenberg explicitly recommended that Evonik consider 'larger dividend cuts and potentially breaking up the company' to adequately address structural headwinds. M&A; activity at the industry level has been low — only 243 deals in H1 2025 across the broader chemical sector (Deloitte). The trough is the entry point for consolidation that creates scale advantages in production and customer base neither company could achieve alone
• Portfolio diversification into adjacent categories: Evonik's joint venture with Vland Biotech (probiotics, 2023), Novus-Ginkgo Bioworks collaboration (enzyme development, 2024), Adisseo's ruminant specialty division record sales (Dec 2024) — all point to the same strategy: extend beyond the methionine tonne into the broader animal gut health, nutrition optimisation, and sustainability service ecosystem	• Pricing discipline and coordinated market signalling: the January 2025 coordinated price increases by Evonik (+7%), Adisseo (+5%), and Chinese producer New Hope Liuhe (+15%) demonstrate that the market can sustain periods of rational pricing. Maintaining this discipline requires restraint from incremental volume chasing at the margin — a discipline that is harder to maintain as Chinese capacity grows
• Geographic hub strategy: produce where cost structures allow. Singapore for Asia (Evonik's 340,000t hub), Fujian for Chinese market (Adisseo's $681M investment), US Gulf Coast for Americas. The era of exporting from Europe to all global markets is challenged.	

7.2 What Governments and Regulators Can Do

• Carbon Border Adjustment Mechanism (CBAM): from 2026, CBAM applies to imported goods' embedded carbon. Methionine production in China, using coal-based energy, carries a significantly higher carbon footprint than European or Singaporean production. CBAM will begin to price this. Industry bodies should actively ensure methionine feed additives are appropriately classified within CBAM scope — this is not guaranteed without lobbying

• Strategic feedstock security: methionine synthesis requires acrolein, hydrogen cyanide, and sulphur. European IPEX support for integrated chemical sites (Verbund model) that co-produce these precursors reduces import dependency at the upstream level. Energy access at competitive prices — via renewable energy guarantees for energy-intensive process industry — is the single most impactful government lever available

• Trade policy and anti-dumping mechanisms: the EU has applied anti-dumping duties on Chinese vitamin C and lysine in the past. Methionine has not yet been subject to formal dumping investigations. If Chinese prices fall demonstrably below cost-of-production, EU trade instruments are available — but require formal complaint, economic evidence, and political will to initiate

• R&D support for bio-based routes: green chemistry programmes that fund fermentation-based methionine development create a domestic production alternative that is both lower-carbon and less feedstock-dependent on petrochemical precursors. Horizon Europe and national innovation programmes have not yet prioritised this specifically

• Market transparency and supply security reporting: mandatory reporting of methionine import sourcing by volume and origin - as is done for critical raw materials under the EU CRMA — would make the 87% US import dependency from China visible in policy terms and create pressure for diversification strategies.(Source:Feedstuffs)

CBAM entered its definitive phase on 1 January 2026, requiring EU importers of covered goods to purchase carbon certificates. Methionine — classified as an organic chemical — is not currently within CBAM's defined scope, which covers cement, steel, aluminium, fertilisers, electricity, and hydrogen. The European Commission is studying the extension of CBAM to organic chemicals and polymers; if implemented, this would likely take effect no earlier than 2027–2028. Should methionine be included in that expansion, Evonik's lower-carbon-footprint MetAMINO (approximately 35% below industry average, per Evonik's own lifecycle assessment) would carry a meaningfully lower CBAM cost than coal-energy-derived Chinese imports. This is a "strategic hedge" rather than an immediate financial relief for Western producers.

8 Can AI Close the Cost Gap? Evidence and Realistic Assessment

The question of whether artificial intelligence can help western methionine producers overcome their structural cost disadvantage is one of the most important forward-looking questions in this paper — and it deserves a precise answer rather than a general endorsement of AI's potential.

The global market for AI in chemicals was valued at $1.3 billion in 2024 and is projected to reach $5.2 billion by 2030 at a 25.9% CAGR (Research and Markets 2025). McKinsey estimates that applying generative AI across commercial, R&D, operations, and support functions in energy and materials can create $80–140 billion in value industry-wide. More concretely: 72% of chemical companies that have implemented industrial AI report at least a 2× improvement in some process KPIs; 37% report a 5× improvement (Accenture). 80% of chemical executives say AI will have immense impact on their business within three years (IBM). These figures reflect companies that have implemented industrial AI and report KPI improvements — not the full chemical industry. Separately, only approximately 14% of chemical companies have deployed AI in core production workflows (Gartner / McKinsey estimates); the majority remain at pilot stage.

The honest assessment: AI can deliver meaningful cost reduction in specific process and logistics domains. It cannot eliminate the structural energy cost differential between European and Chinese production, and it cannot substitute for precursor feedstock access. But it can compress the gap — and in a market where the breaking point is defined by the margin between western full cost and Chinese cost, compressing that gap has direct survival value.

Market size estimates for AI in chemicals vary by source: approximately $943M in 2023 (Grand View Research) to $1.3B in 2024 (Research and Markets, February 2025), depending on scope definition.

8.1 Where AI Creates Verified Value in Chemical Manufacturing

AI Application	Mechanism and Evidence	Cost Impact Type
Process optimisation and yield improvement	Real-time AI analysis of reactor conditions, feedstock composition, and temperature/pressure profiles to optimise yield continuously. Documented result: a manufacturer of Ethylene Dichloride (analogous continuous-process chemistry to methionine synthesis) implemented process-based industrial AI and increased yield by €1.7M in under 12 months (Augury/Accenture case study).	Direct — reduces per-tonne production cost
Energy optimisation	AI scheduling of energy-intensive process steps to off-peak grid periods, dynamic adjustment of heat exchange networks, and predictive management of steam generation. For a process where energy is the dominant cost, 5–10% energy reduction represents a structurally significant cost improvement. Deloitte documents AI-driven predictive analytics reducing maintenance costs by 45% in chemical contexts.	Direct — partially closes energy cost gap
Predictive maintenance	Avoiding unplanned shutdowns in continuous-process facilities is extraordinarily high-value. Methionine synthesis involves high-pressure reactors and corrosive intermediates — unplanned downtime is not just a cost event but a safety and capacity reliability event. ML models monitoring vibration, temperature, and pressure sensor data can predict failures days to weeks in advance.	Direct — improves asset utilisation
Demand forecasting and inventory optimisation	AI-driven demand forecasting using seasonal patterns, livestock production cycles, and procurement signals from major customers allows tighter inventory management. In a market where methionine prices fluctuate 3–5% monthly, holding 6 weeks of finished goods versus 3 weeks has significant working capital implications.	Indirect — reduces capital tied up in inventory
Precision nutrition analytics as a service	The most strategically interesting AI application: Evonik's AMINODat and feed formulation tools, Novus's precision nutrition programmes. AI-powered diet optimisation that minimises total amino acid inclusion while maintaining performance targets adds measurable value to the customer. This is not production cost reduction — it is value creation that justifies a premium price for the amino acid itself.	Indirect — supports premium pricing model

R&D acceleration — bio-based route development	McKinsey estimates AI can accelerate chemical R&D cycle times by 25–50%. For bio-based methionine fermentation, AI-driven strain engineering and fermentation parameter optimisation can compress the development timeline for more efficient microbial synthesis routes. The Novus-Ginkgo Bioworks partnership (Sep 2024) explicitly targets AI-powered enzyme development for feed additives.	Long-term — strategic positioning

Sources: Augury/Accenture industrial AI case studies; McKinsey November 2024; Deloitte digital twin studies; IBM chemical industry survey; EY chemicals R&D; transformation report February 2026. McKinsey's estimate that up to 30% of work hours could be automated applies across the full economy; chemical manufacturing, due to its regulatory and safety constraints, is generally expected to adopt AI at a slower pace than the economy-wide average.

8.2 The Realistic Assessment: What AI Can and Cannot Do

Limitations and Constraints	Where AI Is Genuinely Strategic
• AI can optimise an existing process — it cannot change the thermodynamics of methionine synthesis. If the process requires a certain energy input, AI can minimise waste and schedule intelligently, but cannot eliminate the fundamental energy demand	• The Novus-Ginkgo Bioworks partnership is the clearest example of AI being applied at the frontier of what matters most: developing more efficient enzymes that can be produced cost-effectively shifts the entire production economics of bio-based methionine. This is AI working on the structural problem, not around it
• Yield improvements of 1–3% via process AI are meaningful in commodity chemistry but do not close a 30–50% cost gap driven by energy, labour, and regulatory cost differentials. They are necessary but not sufficient	• Evonik's MetAMINO ATLAS — 19 global trials proving bioavailability superiority — is an AI-intensive data operation. Managing, analysing, and communicating 19-site global trial data requires precisely the kind of AI-assisted analysis that converts field data into marketable claims. The science is old; the ability to prove and communicate it at scale is new
• Predictive maintenance benefits require baseline digitisation of plant sensor infrastructure — a capital investment that itself must be justified against the cost-of-delay of Chinese price pressure. Older European chemical facilities may not have the sensor density needed for ML models to function	• Digital twin technology — simulating entire methionine production trains in software — allows virtual testing of process changes before physical implementation, cutting the cost and risk of plant optimisation. Deloitte documents +30% plant efficiency improvements via digital twin implementation in analogous chemical contexts
• The precision nutrition service model is the most structurally promising — it is genuinely difficult to replicate and creates switching costs at the customer level. But it requires sustained investment in data science, farm-level partnerships, and software — capabilities that most traditional feed additive companies do not yet have at scale	• Honest ceiling: The 5–15% figure is an indicative range based on analogous process industry case studies and should not be taken as a committed outcome; results vary significantly by facility digitisation baseline, chemistry type, and implementation depth.

9 The Communication Consequence: Why the Industry Goes Quiet

One consequence of structural margin pressure that is rarely analysed directly: when companies are under cost pressure, communication budgets are cut. When communication budgets are cut, the technical dialogue with customers, integrators, and the broader B2B ecosystem becomes thinner. This creates a counterproductive dynamic precisely when the industry most needs to differentiate on substance.

The animal nutrition sector has seen this pattern before. Cost pressures in 2022–2023 triggered restructuring programmes across Evonik, DSM, and other animal nutrition businesses. Marketing and technical communication were among the first budget lines reduced. The result: a market in which buyers have less technical information available to evaluate quality differences between suppliers, and therefore shift purchasing decisions toward price — which accelerates commoditisation. It is a self-reinforcing dynamic.

The Communication Paradox

In a commoditising market, the rational response to price pressure is to communicate more, not less — to make the technical case for quality differentiation, demonstrate the precision nutrition service value, and build the customer relationships that create switching costs. But the financial pressure that drives commoditisation simultaneously removes the budgets that would fund this communication. Companies that maintain communication investment through the trough emerge with stronger market positions when the cycle turns. Those that cut to zero face a recovery that starts from silence.

10 Scenarios for the Western Animal Nutrition Industry to 2030

Four scenarios, structured around the interaction of Chinese capacity growth and western industry response. These are analytical constructs, not predictions. The market will not follow any of them precisely — but each maps a coherent set of conditions and outcomes.

Scenario	Description	Key Condition / Comment
Scenario A Managed Transition	Chinese capacity adds ~1.5M tonnes as projected. Western producers successfully differentiate on quality, service, and bio-based sustainability credentials. CBAM prices Chinese carbon into the equation from 2026 onward. Methionine price floor around western variable cost. Evonik, Adisseo, and Novus maintain 50–60% of non-Asian markets through service model transition.	Most optimistic, requires industry discipline and regulatory delivery
Scenario B Partial Commoditisation	Chinese capacity arrives faster than western service differentiation. Methionine margins for European producers fall to near-zero by 2028–2029. Evonik exits European methionine production or converts to tolling. Singapore and US hubs maintained. Adisseo fully pivots to Chinese production cost base. Novus restructures around MHA niche. Western animal nutrition industry contracts significantly.	Base case under Berenberg's structural assessment
Scenario C Disruptive Stabilisation	Chinese overcapacity triggers domestic price collapse in China, forcing consolidation of Chinese producers. State support cannot sustain loss-making capacity indefinitely. Global prices rebound from the trough as Chinese capacity rationalises, similar to the vitamin C cycle. Western producers who survived the trough are well-positioned in the recovery.	Historical precedent exists in vitamins; timeline uncertain
Scenario D Trade Policy Intervention	EU initiates formal anti-dumping investigation into Chinese methionine following evidence of below-cost export pricing. Anti-dumping duties of 20–30% partially offset Chinese cost advantage. US follows with Section 232 or ITC action. Protected western production continues, less efficiently than market outcome. Bio-based routes receive accelerated funding under strategic autonomy agenda.	Political will requirement; US already at 87% import dependency from China

The Most Likely Near-Term Path

A combination of Scenarios A and B: selective exit from European production of commodity DL-methionine (moving to Asian hubs for tonnage), combined with aggressive service model development for western markets. The western animal nutrition company of 2030 is probably not primarily a methionine manufacturer. It is a precision nutrition service provider that happens to produce methionine as part of a broader amino acid and gut health portfolio, manufactured at lowest-cost locations globally. The molecule becomes an entry point; the margin comes from the service layer.

11 Closing: The Industry at a Structural Crossroads

Methionine is a microcosm of a broader story playing out across European specialty chemistry: technology leadership built over decades, under structural pressure from Chinese industrial policy and scale, in a regulatory environment that adds cost rather than removing it, in an energy environment that has permanently shifted against European production. The question is not whether the pressure is real — it unambiguously is. The question is what remains in western producers' hands that cannot be replicated by state-backed Chinese scale.

The answer exists. It lies in the service layer — in the nutritional science, the farm-level performance data, the customer relationships, the regulatory trust, and the sustainability credentials that Chinese commodity producers do not possess. Evonik's 35%-below-average carbon footprint for MetAMINO, its bioavailability data from 19 global trial sites, and its joint venture strategy for probiotics in China all point toward a company that understands what it is becoming. The financial window to complete that transition while the methionine cash flow still supports investment is narrowing. Berenberg estimates it closes around 2030.

The Three Questions That Define the Next Five Years

1. Can western producers transition from selling tonnes to selling outcomes fast enough — before the methionine margin that funds the transition erodes?
2. Will CBAM, anti-dumping instruments, and energy policy create a regulatory floor that gives western producers enough time to complete the transition — or will the market move faster than the policy?
3. Can AI-assisted process optimisation, bio-based route development, and precision nutrition analytics close enough of the cost gap to make the transition economically viable on a standalone basis — or does it require both AI and policy support simultaneously?

There is no doomsday here, but there is urgency. The animal nutrition industry has navigated commodity cycles before. What is different about the current one is its structural character: Chinese capacity is being added not as a market response to demand but as an industrial policy objective. That changes the recovery timeline and the nature of what is required to survive it. The companies that recognise this — and act on it now — have the best chance of being the ones that are still independent, profitable, and strategically positioned in 2030.

Sources and References

1. Berenberg (January 2026). Evonik Industries AG analyst note. China positioned to add ~1.5M tonnes cumulative methionine capacity by early 2030s. Methionine may become 'structurally low-margin chemicals by ~2030.' Evonik EBITDA from methionine ~€300M in 2024. Prices projected to fall low-single-digit% 2026–2027. via Investing.com January 7, 2026. (Berenberg)
2. Barclays (March 2026). Evonik upgrade as methionine disruptions support pricing. Asia holds 64% of global methionine capacity (China 35%, rest of Asia 29%). Evonik holds 44% of non-Asian capacity. ~€450M EBITDA delta if Asian tightness shifts volume. 2026 EBITDA estimate lifted to €1.89B. via Investing.com March 2026.
3. Evonik Industries AG press releases 2025–2026. March 2026: +10% MetAMINO price increase. May 2025: +5–8% price increase. March 2025: Technical upgrade Antwerp/Wesseling, 8–10 week partial shutdown. August 2024: Singapore capacity expanded +40,000t to 340,000t/yr. animal-nutrition.evonik.com
4. Mordor Intelligence (2026). Methionine Market Report. Market at 1.94M tonnes in 2025, reaching 2.64M tonnes by 2030 at 6.41% CAGR. Adisseo $681.2M commitment to 150,000t/yr Fujian facility (start-up 2027). mordorintelligence.com
5. Mordor Intelligence (Oct 2025). China Feed Amino Acids Market. Total Chinese amino acid capacity >4.89M tonnes/year. January 2025 coordinated price hikes: Adisseo +5%, New Hope Liuhe +15%, Evonik +7%. Landed costs in China up 5–7%.
6. ResearchAndMarkets / Institute for Feed Education and Research (2024). US sourced 87% of methionine imports from China in 2024. Global chicken meat production reaching record 104.9M tonnes in 2025 (USDA FAO).
7. Industry Research Biz (Dec 2025). Methionine Market. Evonik ~30% global supply 2024; Adisseo ~25%. Sichuan Hebang new 70,000t line completed 2025. Market $8.14B estimated 2026, reaching $15.56B by 2035 at 7.47% CAGR.
8. Grand View Research (2025). Methionine Market Report. Market estimated $3.67B in 2024, reaching $6.2B by 2030 at 9.2% CAGR. Poultry feed ~46% of methionine use. Aquaculture fastest-growing application.
9. Precedence Research (Feb 2025). Global methionine market $3.7B in 2024, growing to $8.86B by 2034 at 9.13% CAGR. Asia-Pacific 53% market share in 2024. Evonik Singapore facility: after Aug 2024 expansion 'largest methionine production facility in world with market share over 40%.'
10. Procurement Resource (2024–2025). DL-Methionine price trends. H1 2024 upward trajectory driven by ammonia/methanol cost increases and China seasonal demand. Red Sea logistics disruptions supporting H2 2024 prices. procurementresource.com
11. Feedinfo Summit (Sep 2023). Global feed additives market outlook. Zhejiang NHU new DL-methionine unit opening H2 2023. Destocking dynamics and cautious buying trends. feedinfo.com
12. McKinsey (Nov 2024). 'How AI Enables New Possibilities in Chemicals.' Gen AI estimated to create $80–140B value in energy and materials. Chemical industry R&D; spending $13B vs Amazon's $73B technology spend.
13. Research and Markets (Feb 2025). Artificial Intelligence in Chemicals report. AI chemicals market $1.3B in 2024, reaching $5.2B by 2030 at 25.9% CAGR.
14. Augury / Accenture. Industrial AI in Chemical Manufacturing. 72% of chemical companies report minimum 2× improvement in process KPIs. 37% report 5× improvement. Ethylene Dichloride yield improvement €1.7M in <12 months.
15. EY (Feb 2026). 'Transforming Chemicals R&D; with AI.' Global chemicals industry $5.7T in 2024. Early adopters seeing gains in speed, cost savings, and market responsiveness. AI accelerating R&D; cycle times.
16. Evonik (Apr 2025). China Feed Industry Expo 2025 press release. MetAMINO carbon footprint ~35% below industry average. Vland Biotech JV: Ecobiol probiotic, first registered Bacillus subtilis product in China.
17. Novus International / Ginkgo Bioworks (Sep 2024). Partnership announcement. AI-powered enzyme development for feed additive applications.
18. ChemChina / Adisseo (Feb 2025). '2024 double-digit revenue and gross profit growth.' Ruminant products division new single-month sales record December 2024.
19. IMP InterMediaPartners (2026). Cross-reference: 'The End of Just-in-Time' Paper 01, April 2026 — supply chain context, Red Sea disruption cost data, chemical industry stability outlook.